These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 28711882)

  • 21. Aberrant activation of the type I interferon system may contribute to the pathogenesis of anti-melanoma differentiation-associated gene 5 dermatomyositis.
    Zhang SH; Zhao Y; Xie QB; Jiang Y; Wu YK; Yan B
    Br J Dermatol; 2019 May; 180(5):1090-1098. PubMed ID: 29947075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma-Derived Exosomal hsa-miR-4488 and hsa-miR-1228-5p: Novel Biomarkers for Dermatomyositis-Associated Interstitial Lung Disease with Anti-Melanoma Differentiation-Associated Protein 5 Antibody-Positive Subset.
    Zhong D; Wu C; Xu D; Bai J; Wang Q; Zeng X
    Biomed Res Int; 2021; 2021():6676107. PubMed ID: 34368354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel susceptibility alleles in HLA region for myositis and myositis specific autoantibodies in Korean patients.
    Kang EH; Go DJ; Mimori T; Lee SJ; Kwon HM; Park JW; Park MH; Song EY; Ha YJ; Lee EY; Lee YJ; Lee EB; Song YW
    Semin Arthritis Rheum; 2019 Oct; 49(2):283-287. PubMed ID: 30952422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
    Ye Y; Fu Q; Wang R; Guo Q; Bao C
    J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome.
    Zuo Y; Ye L; Chen F; Shen Y; Lu X; Wang G; Shu X
    Front Immunol; 2022; 13():845988. PubMed ID: 35320936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies.
    Chen F; Li S; Wang T; Shi J; Wang G
    Am J Med Sci; 2018 Jan; 355(1):48-53. PubMed ID: 29289262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.
    Huang K; Vinik O; Shojania K; Yeung J; Shupak R; Nimmo M; Avina-Zubieta JA
    Rheumatol Int; 2019 Nov; 39(11):1971-1981. PubMed ID: 31375890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytokeratin 19 fragment is associated with severity and poor prognosis of interstitial lung disease in anti-MDA5 antibody-positive dermatomyositis.
    Gui X; Ma M; Ding J; Shi S; Xin X; Qiu X; Zhang Y; Qiu Y; Cao M; Huang M; Cao M; Dai J; Cai H; Xiao Y
    Rheumatology (Oxford); 2021 Aug; 60(8):3913-3922. PubMed ID: 33501503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
    Motegi SI; Sekiguchi A; Toki S; Kishi C; Endo Y; Yasuda M; Ikeuchi H; Sakairi T; Hara K; Yamaguchi K; Maeno T; Hiromura K; Ishikawa O
    Eur J Dermatol; 2019 Oct; 29(5):511-517. PubMed ID: 31617496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis.
    Matsushita T; Mizumaki K; Kano M; Yagi N; Tennichi M; Takeuchi A; Okamoto Y; Hamaguchi Y; Murakami A; Hasegawa M; Kuwana M; Fujimoto M; Takehara K
    Br J Dermatol; 2017 Feb; 176(2):395-402. PubMed ID: 27452897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of usefulness in surfactant protein D as a predictor of mortality in myositis-associated interstitial lung disease.
    Kaieda S; Gono T; Masui K; Nishina N; Sato S; Kuwana M;
    PLoS One; 2020; 15(6):e0234523. PubMed ID: 32525903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis.
    Ceribelli A; Fredi M; Taraborelli M; Cavazzana I; Tincani A; Selmi C; Chan JY; Chan EK; Satoh M; Franceschini F
    Clin Exp Rheumatol; 2014; 32(6):891-7. PubMed ID: 25151986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis.
    Moghadam-Kia S; Oddis CV; Sato S; Kuwana M; Aggarwal R
    Arthritis Care Res (Hoboken); 2016 May; 68(5):689-94. PubMed ID: 26414240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD.
    Horiike Y; Suzuki Y; Fujisawa T; Yasui H; Karayama M; Hozumi H; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Ogawa N; Suda T
    Rheumatology (Oxford); 2019 Dec; 58(12):2143-2152. PubMed ID: 31143953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Three cases report of juvenile dermatomyositis with positive anti-melanoma differentiation associated gene 5 (MDA5) antibody and severe interstitial lung disease and literature review].
    Hou J; Zhou ZX; Li JG; Xu YJ; Ding YC
    Zhonghua Er Ke Za Zhi; 2019 Dec; 57(12):928-933. PubMed ID: 31795559
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis.
    Zuo Y; Ye L; Liu M; Li S; Liu W; Chen F; Lu X; Gordon P; Wang G; Shu X
    Rheumatology (Oxford); 2020 Oct; 59(10):2829-2837. PubMed ID: 32065646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
    Yamaguchi K; Yamaguchi A; Kashiwagi C; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Suzuki M; Kono S; Takemura M; Masubuchi H; Kitahara S; Hara K; Maeno T; Motegi SI; Muro Y; Sakairi T; Hisada T; Kurabayashi M
    Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association Between HLA Alleles and Autoantibodies in Dermatomyositis Defined by Sarcoplasmic Expression of Myxovirus Resistance Protein A.
    Oyama M; Ohnuki Y; Uruha A; Saito Y; Nishimori Y; Suzuki S; Inoue M; Tanboon J; Okiyama N; Shiina T; Nishino I; Suzuki S
    J Rheumatol; 2023 Sep; 50(9):1159-1164. PubMed ID: 37321638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis.
    Sakamoto N; Ishimoto H; Nakashima S; Yura H; Miyamura T; Okuno D; Hara A; Kitazaki T; Kakugawa T; Ishimatsu Y; Satoh M; Mukae H
    Intern Med; 2019 Mar; 58(6):837-841. PubMed ID: 30449789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum interferon-α is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis.
    Horai Y; Koga T; Fujikawa K; Takatani A; Nishino A; Nakashima Y; Suzuki T; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Ida H; Kakugawa T; Sakamoto N; Ishimatsu Y; Mukae H; Hamaguchi Y; Fujimoto M; Kuwana M; Origuchi T; Kohno S; Kawakami A
    Mod Rheumatol; 2015 Jan; 25(1):85-9. PubMed ID: 24716595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.